- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00568477
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation (Rituximab 2006)
Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a prospective, randomized, open, 2-arm, national multi-center study to evaluate the value of rituximab in humoral chronic rejection after renal transplantation in approximately 150-200 patients (75-100 patients each group).
All biopsies will be analysed by Prof. Groene (Heidelberg) and the results immediately communicated to the central managing unit (Munich). Upon receipt, patients with biopsy proven CAN with C4d+ and/or plasma-cells and/or B-lymphocytes within the last 4 weeks before inclusion (centrally confirmed), fulfilling the inclusion/exclusion criteria, will be randomized 1:1 into one of the 2 groups:
Arm 1: Treatment with rituximab Arm 2: Treatment without rituximab Recruitment will last for approximately one year. All patients will be treated with baseline medication of Tacrolimus, MMF, steroids (optional, with same dose as given before study entry) and ACE-inhibitor or AT1-receptor-antagonist. A single dose of 100 mg Methylprednisolone i.v. will be given at baseline (day 0) in both groups (in the rituximab group 30 min before start of the rituximab infusion).
Each patient will be followed for 1 year within protocol, with study visits at 1,3,7 and 14 days (rituximab group), 3, 6 and 12 months followed by a follow-up period of 1 year with a study visit at 24 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 81675
- Technical University of Munich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Renal allograft recipients at least 1 year after transplantation with GFR > 25 ml/min x 1,73m2 (MDRD)
- Single organ recipients of renal allograft
- Patients who have provided informed consent
- Patients who are >= 18 years of age
- Patients who have biopsy proven CAN with C4d+ deposits and/or plasma-cells and/or B-lymphocytes within the last 4 weeks before inclusion
- Patients who are treated with ACE/AT1 Blocker more than 1 week before inclusion
Exclusion Criteria:
- Patients who suffer from HIV infection
- Patients with a history of Hepatitis B
- Patients with Hepatitis C (active/chronic)
- Patients who have a contraindication for the use of rituximab, such as leukopenia or experienced infusion-related adverse events to former antibody treatment
- Patients who showed signs of acute cellular rejection in the biopsy
- Patient has a malignancy or history of malignancy within the last 5 years, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
- Patient has a systemic infection requiring treatment.
- Female patients who are pregnant or lactating
- Patients who have any form of substance abuse, psychological illness or any other condition, which, in the opinion of the investigator, may interfere with the patient's ability to understand the requirements of the study.
- Patients who have a proteinuria >4g/24h
- Patient is unlikely to comply with the visits scheduled in the protocol.
- Patient is simultaneously participating in another investigational drug study or has participated in such study within 28 days before entry in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Treatment with rituximab
|
Rituximab (MabThera): 375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes |
No Intervention: Arm 2
Treatment without rituximab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary objective: To evaluate the benefit of Rituximab in patients with CAN with histologically proven C4d deposits and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts. Secondary objectives: Renal function at 1 year
Time Frame: Graft survival at 1 and 2 years
|
Graft survival at 1 and 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Renal function at 1 year
Time Frame: Graft survival at 1 and 2 years
|
Graft survival at 1 and 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Uwe Heemann, Prof. MD, Technical University of Munich, Klinikum rechts der Isar; Münchner Studienzentrum
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAL-518-HEE-0200-S
- EudraCT-number: 2006-006137-41
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)Active, not recruitingKidney Transplantation | Renal Transplantation | Renal Transplant RecipientUnited States
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
NovartisCompletedOrgan Transplantation, Renal Transplantation
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedKidney Transplantation | Renal TransplantationUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
University of North Carolina, Chapel HillMallinckrodtWithdrawnKidney Transplantation | Renal Transplantation | FSGSUnited States
-
Bristol-Myers SquibbCompletedKidney Transplantation | Graft Rejection | Renal TransplantationUnited States
-
Rabin Medical CenterRecruitingRenal TransplantationIsrael
Clinical Trials on MabThera
-
University of CopenhagenRigshospitalet, DenmarkCompletedFatigue | Keratoconjunctivitis Sicca | Primary Sjögren's Syndrome | Xerostomia | HyposalivationDenmark
-
The Lymphoma Academic Research OrganisationRoche Pharma AGCompleted
-
Medical University of ViennaTerminatedRheumatoid Arthritis | RemissionAustria
-
Assistance Publique - Hôpitaux de ParisHoffmann-La RocheCompleted
-
Karolinska InstitutetActive, not recruitingMultiple Sclerosis, Relapsing-RemittingSweden
-
Hoffmann-La RocheCompletedLymphocytic Leukemia, ChronicGermany
-
Hoffmann-La RocheCompletedLymphocytic Leukemia, ChronicGreece
-
Hoffmann-La RocheCompletedOff-Label UseSpain, France, Italy, United Kingdom, Germany
-
University Hospital, ToursRoche Pharma AG; French Innovative Leukemia OrganisationCompleted
-
Anders SvenningssonVästerbotten County Council, SwedenCompletedProgressive Multiple SclerosisSweden